Skip to main content
SpringerLink
Log in

Current treatment considerations in community-acquired pneumonia in older patients

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lieberman D, Lieberman D. Community-acquired pneumonia in the elderly. A practical guide to treatment. Drugs Aging 2000 Aug; 17(2): 93–105

    Article  PubMed  CAS  Google Scholar 

  2. Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs 1998 Jan; 55(1): 31–45

    Article  PubMed  CAS  Google Scholar 

  3. Perry CM, Goa KL. Community-acquired pneumonia and its management. The role of levofloxacin. Dis Manage Health Outcomes 2001; 9(1): 43–64

    Article  Google Scholar 

  4. Barman Balfour JA, Lamb HM. Management of community-acquired pneumonia. The role of clarithromycin. Dis Manage Health Outcomes 1999 Oct; 6(4): 225–39

    Article  Google Scholar 

  5. Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly: clinical and nutritional aspects. Am J Respir Crit Care Med 1997; 156: 1908–14

    PubMed  CAS  Google Scholar 

  6. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–26

    Google Scholar 

  7. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50

    Article  PubMed  CAS  Google Scholar 

  8. Marrie TJ, Lau CY, Wheeler SL, et al. A critical pathway for the treatment of community-acquired pneumonia. Drugs 1999; 58 Suppl. 2: 273–5

    Article  Google Scholar 

  9. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway of treatment of community-acquired pneumonia. JAMA 2000 Feb 9; 283: 749–55

    Article  PubMed  CAS  Google Scholar 

  10. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31(2): 347–82

    Article  PubMed  CAS  Google Scholar 

  11. Zhanel GG, Walkty A, Vercaigne L, et al. The new fluoroquinolones: a critical review. Can J Infect Dis 1999; 10(3): 207–238

    PubMed  CAS  Google Scholar 

  12. Dunn CJ, Barradell LB. Azithromycin: a review of its pharmacological properties and use as a 3-day therapy in respiratory tract infections. Drugs 1996; 51: 483–505

    Article  PubMed  CAS  Google Scholar 

  13. Early intravenous to oral switch therapy in community-acquired pneumonia is advantageous. Drugs Ther Perspect 1997; 10 (3): 10-3

  14. Rhew DC, Hackner D, Henderson L, et al. The clinical benefit of in-hospital observation in ‘low-risk’ pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest 1998; 113: 142–6

    Article  PubMed  CAS  Google Scholar 

  15. Ortquist A, Hedlund J, Burman LA, et al. Randomized trial of a 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people: Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351: 399–403

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Current treatment considerations in community-acquired pneumonia in older patients. Drugs Ther. Perspect 17, 5–8 (2001). https://doi.org/10.2165/00042310-200117210-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117210-00002

Keywords

Search

Navigation